Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Low Confidence ObservationalOutcomes summary
IRB-approved pilot study in 2 relatively healthy adults (58-year-old Asian male and 68-year-old Caucasian female) assessing safety and tolerability of intravenous BPC-157; participants received 10 mg and 20 mg infusions over consecutive days with comprehensive blood work and vital sign monitoring before and after each infusion; no measurable adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers were observed, and no side effects were reported.
Limitations
Very small sample size (n=2), short duration, single-center study, lack of placebo control, limited dosing range tested, and both participants had prior exposure to BPC-157; generalizability to larger populations requires confirmation in larger trials.
Notes
Primary source: Alternative Therapies (2025; 31(5):20-24).